News
08/16/2001
Press Release
Isonics Receives First Shipment of Commercially Produced Silicon-28 Trichlorosilane
GOLDEN, CO August 16, 2001– Isonics Corporation (NasdaqSC: ISON /ISONW) (OTCBB: ISONL /ISONZ) and (Frankfurt: IO9) a leader in the development of isotopically pure silicon-28 wafers for semiconductor device manufacture announced that it has received the first commercially produced Si-28 Trichlorosilane (Si-28 TCS) from its Russian supplier. Isonics will characterize the material to establish its conformance with Isonics’ and industry specifications.
Dr. Stephen Burden, Isonics’ Vice President of semiconductor materials commented, “We are quite encouraged in receiving this material from our trusted isotope supplier. We will perform rigorous evaluations at a number of independent laboratories. Once we have qualified this new product form, we plan to place an order for 200 kg to replace that Si-28 which was supposed to have been delivered by Eagle-Picher, and plan to use it to produce single crystal bulk wafers for customer evaluations.
“Trichlorosilane is a different chemical form of silicon-28 than we had previously received from this supplier and which we were expecting to obtain from Eagle-Picher. This form will require much less processing to turn it into a useable product and should be more economical in the long-run. We are informed that quantities of silicon-28 will be limited only by our willingness to place purchase orders.”
Isonics is a world leader in isotopically engineered materials and produces isotopically pure silicon-28 chemicals and wafers for the semiconductor industry. Isonics also markets and sells stable isotopes for the health care industry such as carbon-13 for diagnostic breath tests and drug design, and oxygen-18 for positron emission tomography (PET) imaging. Stable isotopes can be thought of as ultra pure materials. For additional information visit www.isonics.com.
Except for historical information contained herein, this document contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements involve known and unknown risks and uncertainties that may cause the Company’s actual results or outcomes to be materially different from those anticipated and discussed herein. Further, the Company operates in industries where securities values may be volatile and may be influenced by regulatory and other factors beyond the Company’s control. Other important factors that the Company believes might cause such differences are discussed in the risk factors detailed in the Company’s 10-KSB for the year ended April 30, 2000, and its quarterly report on Form 10-QSB for the nine months ended January 31, 2001, both as filed with the Securities and Exchange Commission, which include the Company's cash flow difficulties, dependence on significant customers, and rapid development of technology, among other risks. In assessing forward- looking statements contained herein, readers are urged to carefully read all cautionary statements contained in the Company’s filings with the Securities and Exchange Commission. |
